REG - Polarean Imaging PLC - Comment re: share purchase

Polarean ImagingAnnouncement

15/01/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240115:nRSO6114Za&default-theme=true

RNS Number : 6114Z  Polarean Imaging PLC  15 January 2024

 

Polarean Imaging Plc

("Polarean" or the "Company")

 

Comment re: share purchase

 

Polarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in
advanced magnetic resonance imaging ("MRI") of the lungs, notes the TR-1
announcements released on 12 January 2024 showing the sale of 9.5 million
Polarean shares held by Amati Global Investors Ltd to NUKEM Isotopes GmbH
("NUKEM Isotopes"), a strategic partner and investor in the Company. This
transaction highlights the significant support NUKEM Isotopes has in Polarean,
and has increased NUKEM Isotopes's Polarean holding to 10.458%.

 

NUKEM Isotopes GmbH is a leading trading company for stable isotopes used in
different fields for various applications. They have established reliable
partnerships with gas manufacturers for the production of highly pure noble
gases. The company is located in Alzenau, Germany.

Enquiries:

 

 Polarean Imaging plc                                        www.polarean.com / www.polarean-ir.com (http://www.polarean-ir.com)
 Christopher von Jako, Ph.D, Chief Executive Officer         Via Walbrook PR
 Charles Osborne, Chief Financial Officer

 Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)                                  +44 (0)20 7710 7600
 Nicholas Moore / Samira Essebiyea / Kate Hanshaw (Healthcare Investment
 Banking)
 Nick Adams / Nick Harland (Corporate Broking)

 Walbrook PR         Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
 Anna Dunphy / Phillip Marriage          Mob: +44 (0)7876 741 001 / +44 (0)7867 984 082

 

About Polarean (www.polarean.com)

 

The Company and its wholly-owned U.S. subsidiary, Polarean, Inc. are
revenue-generating, medical imaging technology companies. The Company aspires
to revolutionise pulmonary medicine by bringing the power and safety of MRI to
the respiratory healthcare community which is desperately in need of new
modern solutions to evaluate lung function. Polarean is dedicated to
researching, developing, and commercialising these novel imaging solutions
with their non-invasive and radiation-free functional MRI platform. The
Company strives to address the global unmet medical needs of more than 500
million patients worldwide suffering from chronic respiratory disease.
Polarean is a leader in the field of hyperpolarisation science and has
successfully developed the first and only hyperpolarised Xenon MRI contrast
agent (XENOVIEW™) to be FDA-approved in the United States. The Company also
commercialises the systems, software, and accessories to support fully
integrated modern respiratory imaging operations. Founded in 2012, with
offices in Durham, NC, and London, United Kingdom, Polarean is committed to
increasing global awareness of and broad access to its XENOVIEW MRI technology
platform. For the latest news and information about Polarean, please visit
www.polarean.com (http://www.polarean.com) .

 

PLC-RNS-2326

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCZZGMMMDKGDZM